Comparative Pharmacology
Head-to-head clinical analysis: SOMOPHYLLIN CRT versus THEOBID JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOMOPHYLLIN CRT versus THEOBID JR.
SOMOPHYLLIN-CRT vs THEOBID JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular cAMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.
Inhibits phosphodiesterase, increasing intracellular cAMP; causes bronchodilation, central nervous system stimulation, and positive inotropic/chronotropic effects.
Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/mL.
300 mg orally every 12 hours, extended-release tablet. Titrate to serum theophylline concentration of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 8-10 hours in adults (non-smokers); prolonged to 12-16 hours in elderly or hepatic impairment; reduced to 4-6 hours in smokers (CYP1A2 induction).
3-8 hours in adults; prolonged in neonates, cirrhosis, heart failure (up to 30 hours). Tobacco smoking induces clearance (half-life 4-5 hours).
Primarily hepatic metabolism (90%) via CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for ~10% in adults, with minor biliary/fecal elimination (<1%).
Hepatic metabolism (90%), renal excretion of unchanged drug (10%). Metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator